Compare CLPS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPS | NRSN |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | Hong Kong | Israel |
| Employees | N/A | 16 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.8M | 26.5M |
| IPO Year | 2017 | N/A |
| Metric | CLPS | NRSN |
|---|---|---|
| Price | $1.00 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 27.4K | ★ 108.5K |
| Earning Date | 03-06-2026 | 03-31-2026 |
| Dividend Yield | ★ 14.76% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $583.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.63 |
| 52 Week High | $1.88 | $2.52 |
| Indicator | CLPS | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 61.17 | 40.83 |
| Support Level | $0.85 | $0.74 |
| Resistance Level | $1.05 | $0.75 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 83.20 | 11.87 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.